Back to Search Start Over

Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: a comprehensive Argentine study of inhibitor risks.

Authors :
Rossetti, L. C.
Szurkalo, I.
Radic, C. P.
Abelleyro, M. M.
Primiani, L.
Neme, D.
Candela, M.
Bianco, R. P.
Tezanos Pinto, M.
Larripa, I. B.
Brasi, C. D.
Source :
Haemophilia. Jul2013, Vol. 19 Issue 4, p511-518. 8p. 1 Diagram, 3 Charts.
Publication Year :
2013

Abstract

Inhibitor development against exogenous factor VIII is a severe impairment of replacement therapy affecting 18% of Argentine patients with severe haemophilia A ( HA). To study the molecular predisposition for inhibitor development, we genotyped 260 HA patients with and without inhibitors, countrywide. The inhibitor-positive population (19 transients, 15 low responders, LR and 70 high responders, HR) of 104 severe- HA patients showed 59 Inv22 (intron 22 inversions), 18 small ins/del-frameshifts, 12 gross deletions, 12 nonsense, one splicing defect and two missense, p.Arg531Pro and p.Leu575Pro, both LR and thought to impair FVIII A2 domain secondary structure. In addition, a patient with mild HA and HR showed the missense p.Glu1704Lys associated with two neutral intronic substitutions potentially affecting the A3 domain. A case/control study (84/143) permitted estimation of F8 genotype-specific inhibitor risks [ OR; prevalence ( CI)] in severe- HA patients classifying a high-risk group including multi-exon deletions [3.66; 55% (19-100)], Inv22 [1.8; 24% (19-100)] and nonsense in FVIII- LCh [1.2; 21% (7-59)]; an average risk group including single-exon deletions, indel frameshifts and nonsense- HCh; and a low-risk group represented by missense defects [0.14; 3% (0.6-11)]. Analysis of inhibitor concordance/discordance in related patients indicated additional genetic factors other than F8 genotype for inhibitor formation. No significant inhibitor-predisposing factors related to FVIII product exposure were found in age- and F8 genotype-stratified populations of severe- HA patients. In conclusion, the Argentine HA patient series presents similar global and mutation-specific inhibitor risks than the HA database and other published series. This case-specific information will help in designing fitted therapies and follow-up protocols in Argentina. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13518216
Volume :
19
Issue :
4
Database :
Academic Search Index
Journal :
Haemophilia
Publication Type :
Academic Journal
Accession number :
88236074
Full Text :
https://doi.org/10.1111/hae.12105